Subsense
Subsense, founded in 2021 in Palo Alto, USA, develops a nanoparticle-based non-surgical brain-computer interface (BCI) that records and modulates neural activity without implant surgery.
About
Subsense, founded in 2021 in Palo Alto, USA, develops a nanoparticle-based non-surgical brain-computer interface (BCI) that records and modulates neural activity without implant surgery. Its approach involves intranasally administered nanoparticles that cross the blood-brain barrier, paired with dedicated hardware and signal processing.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 1
Founders / team· 2
Funding history
- 2025-12Seed$10M
Investors · Golden Falcon CapitalSource · SVTR Weekly #135 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Subsense
Nanoparticle-based non-surgical BCI for implant-free recording and modulation of neural activity
Seed · $10M · 2025-12
$10M
United States
BusinessLatest roundTotal raisedDate- Blackrock Neurotech
Develops brain-computer interface technology designed to help patients with paralysis or other neurological conditions control digital devices and regain mobility
Undisclosed · $200M · 2024-05
$200M - Axoft
Implantable brain-computer interfaces using biomimetic materials, with flexible neural electronics for high-resolution neural recording and stimulation
Series A · $60M · 2026-05
$60M - Coherence Neuro
Closed-loop brain-computer interface system SOMA, using a wireless implant to decode tumor electrical signals in real time and deliver personalized electrical stimulation to treat brain tumors and other cancers
Seed · 2026-10
—
China
BusinessLatest roundTotal raisedDate- 芯生视界
Invasive brain-computer interface system, a 10,000-channel all-in-one implantable "neural GPU"
Seed · $14M · 2026-06
$14M - Mindtrix
Invasive brain-computer interface product development
Angel · $21M · 2026-04
$21M - Qiangnao
Non-invasive brain-computer interfaces and intelligent bionic prostheses
Series D+ · $20M · 2025-11
$20M
Europe
BusinessLatest roundTotal raisedDate- Neurosoft Bioelectronics
Flexible, stretchable, non-penetrating brain-computer interfaces and neural electrodes to record/stimulate brain-surface activity
Seed · $20M · 2026-05
$20M - MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation, on-chip processing and wireless transmission, for BCI and active implant makers
Undisclosed · 2026-10
— - InBrain Neuroelectronics
Graphene-based brain-computer interface technology for neurological disorders such as Parkinson's disease.
Series B · $50M · 2024-11
$50M
Other / unspecified
BusinessLatest roundTotal raisedDate- 脑思科技
Brain-computer interface electrodes and neural decoding systems
Angel · $10M · 2026-05
$10M - Brain.space
Non-invasive brain monitoring platform with real-time neural data analysis
Series A · $11M · 2025-03
$11M - Hemispheric
AI analysis of non-invasive brain activity data to aid psychiatric diagnosis
2026-07
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 18 at a nearby stage · 35 in United States
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 31 in United States
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in United States
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in United States
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in United States
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 5 at a nearby stage · 14 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.